Business Context and Reporting Period
This Form 6-K was filed by NLS Pharmaceutics Ltd., not Newcelx Ltd., and covers September 2021 (Report No. 2). The filing reports a September 27, 2021 Standby Equity Distribution Agreement with YA II PN, Ltd. (“YA”).
Financing and Key Terms
- NLS may sell up to $20.0 million of common shares to YA, at its option, during the three-year term of the agreement.
- Shares sold under the facility will generally be priced at 92% of the lowest daily volume-weighted average price during the applicable five-trading-day pricing period.
- YA may not purchase shares that would cause it to own more than 9.99% of NLS’s outstanding shares.
- NLS has agreed to sell YA 1,313,232 shares at $1.90 per share, for aggregate gross proceeds of approximately $2.5 million. Closing was expected within 15 business days after execution.
- NLS must pay YA a $400,000 commitment fee, equal to 2% of the facility amount. Half was payable upon execution and the remainder within 12 months; payment may be made in cash or shares.
- NLS is not required to draw on the facility, and there are no minimum funding commitments or penalties for non-use.
Use of Proceeds and Capital Structure Implications
Net proceeds from the equity facility and the initial equity investment are intended to fund ongoing clinical and pre-clinical development activities and general corporate purposes. Future proceeds and dilution will depend on the number of shares issued and market prices.
NLS agreed to register the shares eligible for sale under the facility, the initial investment shares, and any shares issued for the commitment fee within 30 days of execution.
Revenue, Profit, Cash Flow, Debt, and Liquidity
The filing does not provide revenue, profitability, cash flow, margin, debt, cash balance, or liquidity metrics. It also does not quantify the company’s existing funding requirements or runway.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative operating or financial results. The principal disclosed change is the establishment of a potential $20.0 million equity financing facility and the commitment to issue 1,313,232 shares in an initial investment.
Outlook, Risks, and Unusual Items
- Access to the facility is discretionary and does not assure that NLS will raise the full $20.0 million.
- Actual proceeds will depend on market prices and the number of shares sold.
- Issuances under the facility, the initial investment, and any shares used to pay the commitment fee may materially dilute existing shareholders.
- The 8% discount to the applicable market price may increase dilution and financing costs.
- The financing is intended to support clinical and pre-clinical development, which carries the customary risks of development delays, unsuccessful results, and additional funding needs.
- YA and its affiliates are prohibited from short selling or hedging the shares during the facility term.
- The transactions rely on exemptions from registration under Section 4(a)(2) of the Securities Act, subject to required registration of the registrable shares.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing names NLS Pharmaceutics Ltd., while the request metadata names Newcelx Ltd.
- Verify whether the 1,313,232-share initial investment closed and the actual proceeds received.
- Review subsequent filings for drawdowns under the equity facility, shares issued, pricing, and cumulative dilution.
- Confirm payment of the $400,000 commitment fee and whether it was paid in cash or shares.
- Review Exhibit 99.1 for the complete terms, conditions, limitations, and termination provisions of the agreement.
- Assess the company’s latest cash position, operating cash burn, clinical pipeline status, and expected financing runway, none of which are provided in this filing.